in obesity (1, 2) and essential hypertension (3, 4) has led to the hypothesis that insulin plays a major role in the development of arterial hypertension (5, 6) . The prohypertensive actions of insulin include antinatriuresis, trophic effects on vascular smooth muscle, and activation of muscle sympathetic nerve activity (7, 8).
Insulin-induced sympathetic activation has been suggested as a cause of arterial pressure elevation. Infusion of insulin during euglycemic clamp increased plasma norepinephrine levels in experimental animals (9, 10) and in humans (11) (12) (13) (14) . Sympathoexcitatory effects of insulin were later confirmed in investigations directly recording muscle sympathetic nerve activity. Insulin infusion augmented sympathetic outflow to skeletal muscle in humans (12, 13, 15) and to the hindlimb in normotensive rats (16, 17) . The increase inactivity appeared to be directed to muscle, since no alterations were observed in skin sympathetic fibers in humans (13), or in renal or adrenal sympathetic activity in normotensive rats (16) .
In rats, a pressor role for insulin-induced sympathetic activation has been suggested by several studies. For example, insulin-generated elevations in heart rate and arterial pressure were prevented by ganglionic blockade (18 A second indirect mechanism of sympathetic stimulation is related to the vasodilatory effects of infused insulin (7, 20) . Insulin-induced vasodilation in skeletal muscle can lead to small decreases in arterial pressure, thereby inducing baroreceptor-mediated increases in sympathetic activity (7, (13) (14) (15) 
Direct Neural Mechanisms
Insulin may evoke sympathetic activation through a number of direct mechanisms. For instance, insulin may affect norepinephrine release from adrenergic nerve endings (9, 18) . Countering this possibility, Lembo et al. (14) failed to detect increases in forearm norepinephrine levels during local insulin infusion in humans.
The fact that only systemic insulin administration increased n0repinephrine release suggested that the sympathoexcitatory effects were mediated by a central neural mechanism (14) .
Landsberg (6) andothers(11)suggested asympathoexcitatory roleof insulin in the central nervous system. In an early study, a low dose of insulin injected into the carotid arteries of dogs increased blood pressure before a fall in blood glucose (27) . A relationship between insulin sensitive regions in the hypothalamus and sympathetic activity was later established in experiments using gold thioglucose in mice (28) . In these studies, changes in cardiac norepinephrine turnover during feeding and caloric restriction were abolished by gold thioglucose lesions of the ventromedial hypothalamus, suggesting that hypothalamic regions provide an important link between insulin-mediated glucose metabolism and sympathetic nervous system activity.
Results from euglycemic clamp studies in humans point to a mechanism of insulin delivery into the central nervous system. In these experiments, plasma norepinephrine and sympathetic nerve activity continued to rise even after plasma insulin levds were at a steady state level or declining (11, observed when insulin is administered systemically during euglycemic clamp (see Figure 1 ). Thus, direct central neural administration of insulin generates a pattern of sympathetic activation similar to that produced by systemic insulin. These data strongly suggest that hyperinsulinemia produces sympathetic excitation through effects on the centzal nervous system.
We reasoned that if infusion of insulin into the third cerebralventricle increases lumbar nerve activity, destruction of third ventricular structures should abolish increases in sympathetic outflow to systemic euglycemic hyperinsulinemia (17) . To test this hypothesis, we subsequently lesioned tissues surrounding the anteroventral portion of the third ventricle (AV3V), a region clearly implicated in In summary, these studies provide important evidence supporting the concept that insulin acts within the central nervous system to increase sympathetic activity. Further, they suggest that AV3V-related structures are critical for insulininduced elevations in sympathetic outflow.
In light of these findings, it should be remembered that AV3V lesions protect against several forms of experimental hypertension (37). Our demonstration of decreased sympathetic activation to insulin in AV3V-lesioned rats suggests a role for the AV3V region in hypertension characterized by insulin resistance and hyperinsulinemia. 
